AP4E1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma cell line, featuring targeted disruption of the AP4E1 gene. This product offers a loss-of-function model for investigating the AP-4 adaptor protein complex in a polyclonal background, ensuring representation of diverse genetic edits while maintaining consistent gene disruption. As a polyclonal population, it is particularly suited for applications requiring bulk cell responses, such as drug screening and functional genomics, without the limitations of clonal variation.
A-549 cells are a well-established human alveolar basal epithelial adenocarcinoma cell line commonly used in cancer biology, drug response, and membrane trafficking studies. These adherent cells retain characteristics of type II pneumocytes and exhibit active mTORC1 signaling, making them a relevant host for studying AP4E1-mediated autophagy and endosomal sorting in a lung adenocarcinoma context. The A-549 background provides a robust platform for examining how loss of AP4E1 influences both basal and stress-induced cellular processes.
AP4E1 encodes the epsilon subunit of the heterotetrameric AP-4 complex, which also comprises AP4B1, AP4M1, and AP4S1, and associates with clathrin to sort cargoes from the trans-Golgi network to endosomes. The complex is critically involved in trafficking ATG9A, a transmembrane protein essential for autophagosome formation, and its function is regulated by TFEB and mTORC1 signaling. Downstream targets of AP-4 include ATG9A, APP, and LRP1, while key pathway components such as ATG16L1, WIPI2, LAMP1, and RAB7 participate in autophagosome maturation and lysosomal delivery. Disruption of AP4E1 impairs ATG9A delivery, leading to defective autophagy flux, accumulation of p62, and altered lysosomal biogenesis, ultimately contributing to neurodegeneration-related pathologies.
In the A-549 adenocarcinoma model, AP4E1 knockout allows dissection of autophagy and membrane trafficking pathways within a cancer-relevant setting. Because A-549 cells are dependent on autophagy for survival under metabolic stress, this model reveals vulnerabilities associated with AP-4 dysfunction. The polyclonal format enables consistent gene disruption across the population, facilitating reproducible experiments in drug sensitivity and cellular behavior. Given the genetic link between AP4E1 mutations and hereditary spastic paraplegia type 51 (SPG51) as well as neurodevelopmental disorders, this model may be applied to explore conserved molecular mechanisms underlying these conditions.
Researchers can employ these polyclonal knockout cells for a variety of assays, including autophagy flux analysis via Western blotting for LC3-I/II and p62 in the presence or absence of Bafilomycin A1, and immunofluorescence to assess ATG9A mislocalization. Co-immunoprecipitation of AP-4 subunits confirms complex disruption, while drug sensitivity assays with autophagy-modulating agents elucidate functional consequences. Migration and invasion assays further probe the role of AP4E1 in cancer cell behavior. This product supports membrane trafficking studies, drug discovery for SPG51, and functional genomics approaches such as RT-qPCR for AP-4 gene expression. For further information or custom requests, please contact Ascent Research.
